FortuneRock to List on China's Third Board

FortuneRock (China) Co., a Beijing clinical-stage biotech, has been approved to IPO and list its shares on China's Third Board, the National Equities Exchange and Quotations (NEEQ). Details of the offering have not been disclosed. FortuneRock develops novel, patent-protected recombinant protein drugs. Its lead drug, currently in a late Phase II trial, is a long-acting treatment to prevent low white blood cell count in chemotherapy patients. More details.... Share this with colleagues: // //